These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21787337)

  • 1. Structural and biophysical insight into cholesteryl ester-transfer protein.
    Hall J; Qiu X
    Biochem Soc Trans; 2011 Aug; 39(4):1000-5. PubMed ID: 21787337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein.
    Cunningham D; Lin W; Hoth LR; Danley DE; Ruggeri RB; Geoghegan KF; Chrunyk BA; Boyd JG
    Bioconjug Chem; 2008 Aug; 19(8):1604-13. PubMed ID: 18646836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules.
    Qiu X; Mistry A; Ammirati MJ; Chrunyk BA; Clark RW; Cong Y; Culp JS; Danley DE; Freeman TB; Geoghegan KF; Griffor MC; Hawrylik SJ; Hayward CM; Hensley P; Hoth LR; Karam GA; Lira ME; Lloyd DB; McGrath KM; Stutzman-Engwall KJ; Subashi AK; Subashi TA; Thompson JF; Wang IK; Zhao H; Seddon AP
    Nat Struct Mol Biol; 2007 Feb; 14(2):106-13. PubMed ID: 17237796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
    Gutstein DE; Krishna R; Johns D; Surks HK; Dansky HM; Shah S; Mitchel YB; Arena J; Wagner JA
    Clin Pharmacol Ther; 2012 Jan; 91(1):109-22. PubMed ID: 22130116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein and its inhibition.
    Weber O; Bischoff H; Schmeck C; Böttcher MF
    Cell Mol Life Sci; 2010 Sep; 67(18):3139-49. PubMed ID: 20556633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viability of developing CETP inhibitors.
    Sirtori CR; Mombelli G
    Cardiovasc Ther; 2008; 26(2):135-46. PubMed ID: 18485135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors.
    Castilho MS; Guido RV; Andricopulo AD
    Bioorg Med Chem; 2007 Sep; 15(18):6242-52. PubMed ID: 17604633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits.
    Kee P; Caiazza D; Rye KA; Barrett PH; Morehouse LA; Barter PJ
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):884-90. PubMed ID: 16373610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.